A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication

Abstract

Introduction Despite rising concerns regarding the safety of anti-obesity medications, there is a lack of comprehensive pharmacovigilance investigations utilising real-world data. We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety. Methods We conducted a cross-sectional analysis on ADE cases spontaneously reported to the Korea Adverse Event Reporting System Database (KIDS-KD). ADE reports pertaining to anti-obesity medications prescribed for overweight, obesity (International Classification of Disease, 10th revision (ICD-10) code E66) and abnormal weight gain (ICD-10 code E63.5) were included in the analysis. We performed a disproportionality to detect the association of the system organ class-based ADEs with their seriousness an individual’s sex by estimating reporting odds ratios (RORs) and their 95% confidence intervals (CIs). We performed logistic regression to investigate factors that are substantially associated with increased SAE risks by estimating odds ratio (OR) and their 95% CIs. Results The most common causative anti-obesity medication was phentermine, followed by liraglutide. ADEs associated with psychiatric disorders (ROR = 1.734; 95% CI = 1.111-2.707), liver and biliary system disorders (ROR = 22.948; 95% CI = 6.613-70.635), cardiovascular disorders (ROR = 5.707; 95% CI = 1.965-16.574), and respiratory disorders (ROR = 4.567; 95% CI = 1.774-11.762) were more likely to be serious events. Additionally, men are more likely to experience ADEs related gastrointestinal disorders (ROR = 1.411) and less likely to have heart and rhythm disorders (ROR = 0.507). The risk of SAE incidences was positively correlated with being male (OR = 2.196; 95% CI = 1.296-3.721), dual or triple combination of anti-obesity medications (OR = 3.258; 95% CI = 1.633-6.501 and OR = 8.226; 95% CI = 3.046-22.218, respectively), and concomitant administration of fluoxetine (OR = 5.236; 95% CI = 2.218-12.365). Conclusions Seriousness of anti-obesity medication-related ADEs differs among system-organ class, while sex-related differences in ADE profiles are also present. The predictors substantially increasing risk of SAE incidences include being male, having a higher number of concomitant medications (including multiple combination of anti-obesity medications), and concurrent use of fluoxetine. Nonetheless, further pharmacovigilance investigation and monitoring are needed to enhance awareness on ADEs induced by anti-obesity medications.

A Real-World Data Derived Pharmacovigilance Assessment on Drug-Induced Nephropathy: Implication on Gaps in Patient Care

“…The association of seriousness of drug-induced nephrotoxicity and causative drugs or drug classes was estimated using disproportionality analysis and was expressed in reporting odds ratios (RORs) with corresponding 95% confidence intervals (CIs) and Mantel–Haenszel adjusted p -values. RORs were estimated for specific offending medications or drug classes with at least three SAE reports [ 31 , 32 ]. Univariate analysis was conducted to identify predictors associated with SAEs and certain types of drug-induced nephrotoxicity, and factors included age, causality, sex, and polypharmacy (concurrent administration of at least 5 daily medications).…”

A Real-World Data Driven Pharmacovigilance Investigation on Drug-Induced Arrhythmia Using KAERS DB, a Korean Nationwide Adverse Drug Reporting System

“…Disproportionality analysis was conducted to evaluate the association of medication classes and types with the seriousness of ADEs by estimating reporting odds ratios (RORs) with corresponding 95% confidence intervals (CIs) and Mantel-Haenszel adjusted p-values [57,58]. Medication classes with at least 5 reported cases for both SAEs and nonserious ADEs were subjected to the disproportionality analysis to ensure the reliability of the statistical analyses [58][59][60][61], and medications with at least 3 reported cases for both SAEs and nonserious ADEs were subjected to the disproportionality analysis due to the substantially low number of ADE cases for each medication. Additionally, associations between clinical predictors and the incidence of SAEs were evaluated by disproportionality analysis, and clinical predictors included age, sex, multiple medication therapy (at least 2 concomitant medications), presence of comorbidities, and history of cancer.…”

A Review of Clinical Studies on Acupuncture Application for Abdominal Obesity

“…한방비만학회지 제23권 제2호, 2023 mine이 나타낼 수 있는 정신장애와 같은 부작용이 보고 되고 있다 8) . 수술요법 중 지방흡입술의 경우, 폐색전증, 저혈량 쇼크, 괴사성 근막염 등의 부작용이 보고되고 있 다 9) .…”